Rectal cancer after prolonged sulindac chemoprevention

A case report

Henry T. Lynch, A. G. Thorson, T. Smyrk

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Background. Sulindac is reported to induce regression of colonic adenomas. However, its role as a chemoprophylactic agent for people with familial adenomatous polyposis (FAP) is under consideration. Methods. This case report describes a patient with FAP in whom rectal adenocarcinoma developed 37 years after prophylactic colectomy and 15 months after beginning a course of sulindac. She received endoscopic follow-ups every 3 months during 15 months of 150-mg twice-daily sulindac administration. At 12 months, an endoscopic examination was unremarkable; at 15 months, endoscopic examination revealed several polyps and a fiat ulcerated lesion. Results. Rectal carcinoma developed in a patient 15 months after beginning chemoprophylaxis; there was metastatic adenocarcinoma in 6 of 20 perirectal lymph nodes. In addition to the carcinoma, rectal mucosa contained two adenomas and multiple foci of adenomatous changes in fiat mucosa. Conclusion. Sulindac may not alter the pathogenesis of FAP. Patients undergoing sulindac chemoprevention must be monitored closely, including endoscopic examination. Endoscopic surveillance should include an aggressive biopsy approach because the absence of polyps does not prove the absence of neoplastic change.

Original languageEnglish
Pages (from-to)936-938
Number of pages3
JournalCancer
Volume75
Issue number4
DOIs
StatePublished - 1995

Fingerprint

Sulindac
Chemoprevention
Rectal Neoplasms
Adenomatous Polyposis Coli
Polyps
Adenoma
Mucous Membrane
Adenocarcinoma
Carcinoma
Colectomy
Lymph Nodes
Biopsy

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Rectal cancer after prolonged sulindac chemoprevention : A case report. / Lynch, Henry T.; Thorson, A. G.; Smyrk, T.

In: Cancer, Vol. 75, No. 4, 1995, p. 936-938.

Research output: Contribution to journalArticle

Lynch, Henry T. ; Thorson, A. G. ; Smyrk, T. / Rectal cancer after prolonged sulindac chemoprevention : A case report. In: Cancer. 1995 ; Vol. 75, No. 4. pp. 936-938.
@article{21f80d7ffab94ad3ae744e4de5b94321,
title = "Rectal cancer after prolonged sulindac chemoprevention: A case report",
abstract = "Background. Sulindac is reported to induce regression of colonic adenomas. However, its role as a chemoprophylactic agent for people with familial adenomatous polyposis (FAP) is under consideration. Methods. This case report describes a patient with FAP in whom rectal adenocarcinoma developed 37 years after prophylactic colectomy and 15 months after beginning a course of sulindac. She received endoscopic follow-ups every 3 months during 15 months of 150-mg twice-daily sulindac administration. At 12 months, an endoscopic examination was unremarkable; at 15 months, endoscopic examination revealed several polyps and a fiat ulcerated lesion. Results. Rectal carcinoma developed in a patient 15 months after beginning chemoprophylaxis; there was metastatic adenocarcinoma in 6 of 20 perirectal lymph nodes. In addition to the carcinoma, rectal mucosa contained two adenomas and multiple foci of adenomatous changes in fiat mucosa. Conclusion. Sulindac may not alter the pathogenesis of FAP. Patients undergoing sulindac chemoprevention must be monitored closely, including endoscopic examination. Endoscopic surveillance should include an aggressive biopsy approach because the absence of polyps does not prove the absence of neoplastic change.",
author = "Lynch, {Henry T.} and Thorson, {A. G.} and T. Smyrk",
year = "1995",
doi = "10.1002/1097-0142(19950215)75:4<936::AID-CNCR2820750407>3.0.CO;2-Q",
language = "English",
volume = "75",
pages = "936--938",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Rectal cancer after prolonged sulindac chemoprevention

T2 - A case report

AU - Lynch, Henry T.

AU - Thorson, A. G.

AU - Smyrk, T.

PY - 1995

Y1 - 1995

N2 - Background. Sulindac is reported to induce regression of colonic adenomas. However, its role as a chemoprophylactic agent for people with familial adenomatous polyposis (FAP) is under consideration. Methods. This case report describes a patient with FAP in whom rectal adenocarcinoma developed 37 years after prophylactic colectomy and 15 months after beginning a course of sulindac. She received endoscopic follow-ups every 3 months during 15 months of 150-mg twice-daily sulindac administration. At 12 months, an endoscopic examination was unremarkable; at 15 months, endoscopic examination revealed several polyps and a fiat ulcerated lesion. Results. Rectal carcinoma developed in a patient 15 months after beginning chemoprophylaxis; there was metastatic adenocarcinoma in 6 of 20 perirectal lymph nodes. In addition to the carcinoma, rectal mucosa contained two adenomas and multiple foci of adenomatous changes in fiat mucosa. Conclusion. Sulindac may not alter the pathogenesis of FAP. Patients undergoing sulindac chemoprevention must be monitored closely, including endoscopic examination. Endoscopic surveillance should include an aggressive biopsy approach because the absence of polyps does not prove the absence of neoplastic change.

AB - Background. Sulindac is reported to induce regression of colonic adenomas. However, its role as a chemoprophylactic agent for people with familial adenomatous polyposis (FAP) is under consideration. Methods. This case report describes a patient with FAP in whom rectal adenocarcinoma developed 37 years after prophylactic colectomy and 15 months after beginning a course of sulindac. She received endoscopic follow-ups every 3 months during 15 months of 150-mg twice-daily sulindac administration. At 12 months, an endoscopic examination was unremarkable; at 15 months, endoscopic examination revealed several polyps and a fiat ulcerated lesion. Results. Rectal carcinoma developed in a patient 15 months after beginning chemoprophylaxis; there was metastatic adenocarcinoma in 6 of 20 perirectal lymph nodes. In addition to the carcinoma, rectal mucosa contained two adenomas and multiple foci of adenomatous changes in fiat mucosa. Conclusion. Sulindac may not alter the pathogenesis of FAP. Patients undergoing sulindac chemoprevention must be monitored closely, including endoscopic examination. Endoscopic surveillance should include an aggressive biopsy approach because the absence of polyps does not prove the absence of neoplastic change.

UR - http://www.scopus.com/inward/record.url?scp=0028813830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028813830&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19950215)75:4<936::AID-CNCR2820750407>3.0.CO;2-Q

DO - 10.1002/1097-0142(19950215)75:4<936::AID-CNCR2820750407>3.0.CO;2-Q

M3 - Article

VL - 75

SP - 936

EP - 938

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -